Mayne Pharma Group Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Mayne Pharma Group wird ein Gewinn- und Umsatzwachstum von 99.8% bzw. 15.6% pro Jahr prognostiziert, während der Gewinn pro Aktie um 99.9% pro Jahr wachsen soll.

Wichtige Informationen

110.0%

Wachstumsrate der Gewinne

110.0%

EPS-Wachstumsrate

Pharmaceuticals Gewinnwachstum	19.4%
Wachstumsrate der Einnahmen	11.3%
Zukünftige Eigenkapitalrendite	n/a
Analystenabdeckung	Low
Zuletzt aktualisiert	30 Aug 2024

Jüngste Aktualisierungen zum künftigen Wachstum

Recent updates

Gewinn- und Umsatzwachstumsprognosen

DB:HG6 - Zukünftige Analystenschätzungen und Finanzdaten der Vergangenheit (AUD Millions)
Datum	Umsatz	Gewinne	Freier Cashflow	Bargeld aus operativen Tätigkeiten	Durchschn. Anz. Analysten
6/30/2027	557	18	N/A	N/A	1
6/30/2026	476	-4	N/A	-9	2
6/30/2025	434	-18	N/A	-24	2
6/30/2024	388	-169	-36	-15	N/A
3/31/2024	354	-221	-35	-15	N/A
12/31/2023	319	-274	-34	-15	N/A
9/30/2023	251	-296	-148	-29	N/A
6/30/2023	184	-317	-262	-43	N/A
12/31/2022	59	-257	-287	-64	N/A
9/30/2022	108	-233	-153	-36	N/A
6/30/2022	157	-209	-19	-7	N/A
3/31/2022	250	-151	-13	3	N/A
12/31/2021	342	-93	-7	13	N/A
9/30/2021	372	-151	14	36	N/A
6/30/2021	401	-208	34	59	N/A
3/31/2021	420	-232	56	82	N/A
12/31/2020	439	-256	78	106	N/A
9/30/2020	448	-174	72	109	N/A
6/30/2020	457	-93	65	113	N/A
3/31/2020	467	-196	61	109	N/A
12/31/2019	478	-300	56	106	N/A
9/30/2019	502	-290	40	106	N/A
6/30/2019	525	-279	25	107	N/A
3/31/2019	543	-118	28	117	N/A
12/31/2018	561	43	31	127	N/A
9/30/2018	546	-46	29	124	N/A
6/30/2018	530	-134	27	121	N/A
3/31/2018	526	-146	N/A	111	N/A
12/31/2017	521	-158	N/A	100	N/A
9/30/2017	547	-35	N/A	42	N/A
6/30/2017	573	89	N/A	-15	N/A
3/31/2017	504	90	N/A	-30	N/A
12/31/2016	435	91	N/A	-44	N/A
9/30/2016	351	64	N/A	5	N/A
6/30/2016	267	37	N/A	54	N/A
3/31/2016	238	30	N/A	49	N/A
12/31/2015	209	23	N/A	44	N/A
9/30/2015	175	15	N/A	33	N/A
6/30/2015	141	8	N/A	22	N/A
3/31/2015	137	12	N/A	21	N/A
12/31/2014	133	17	N/A	20	N/A
9/30/2014	138	19	N/A	23	N/A
6/30/2014	143	21	N/A	26	N/A
3/31/2014	135	15	N/A	24	N/A
12/31/2013	126	8	N/A	21	N/A
9/30/2013	105	3	N/A	14	N/A

Analystenprognosen zum zukünftigen Wachstum

Einkommen vs. Sparrate: HG6 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als schnelleres Wachstum als die Sparquote angesehen wird (0.8%).

Ertrag vs. Markt: HG6 wird in den nächsten 3 Jahren voraussichtlich rentabel werden, was als überdurchschnittliches Marktwachstum angesehen wird.

Hohe Wachstumserträge: HG6 wird voraussichtlich in den nächsten 3 Jahren rentabel werden.

Einnahmen vs. Markt: HG6Die Einnahmen des Unternehmens (15.6% pro Jahr) werden voraussichtlich schneller wachsen als der Markt German (5.1% pro Jahr).

Hohe Wachstumseinnahmen: HG6Die Einnahmen des Unternehmens (15.6% pro Jahr) werden voraussichtlich langsamer wachsen als 20% pro Jahr.

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Künftige Eigenkapitalrendite: Unzureichende Daten, um festzustellen, ob die Eigenkapitalrendite von HG6 in 3 Jahren voraussichtlich hoch sein wird

Mayne Pharma Group Zukünftiges Wachstum

Future Kriterienprüfungen 4/6

Wichtige Informationen

Jüngste Aktualisierungen zum künftigen Wachstum

No longer forecast to breakeven

Forecast to breakeven in 2026

Forecast breakeven date pushed back to 2024

Forecast to breakeven in 2023

Recent updates

Full year 2024 earnings released: AU$2.12 loss per share (vs AU$3.86 loss in FY 2023)

No longer forecast to breakeven

New minor risk - Profitability

First half 2024 earnings released: AU$0.88 loss per share (vs AU$1.38 loss in 1H 2023)

Forecast to breakeven in 2026

New minor risk - Share price stability

Mayne Pharma Group Limited to Report Fiscal Year 2024 Results on Aug 23, 2024

Mayne Pharma Group Limited to Report First Half, 2024 Results on Feb 26, 2024

High number of new directors

Mayne Pharma Group Limited Approves Election of Anne Lockwood

CEO, MD & Director recently bought €84k worth of stock

Mayne Pharma Group Limited, Annual General Meeting, Nov 30, 2023

Full year 2023 earnings released: AU$3.86 loss per share (vs AU$3.20 loss in FY 2022)

New minor risk - Financial data availability

Mayne Pharma Group Limited to Report Fiscal Year 2023 Results on Aug 31, 2023

Mayne Pharma Group Limited Announces Retirement of Carolyn Myers from the Board At the End of July 2023

First half 2023 earnings released: AU$0.078 loss per share (vs AU$0.62 loss in 1H 2022)

Mayne Pharma Group Limited to Report First Half, 2023 Results on Feb 28, 2023

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces US Launch of Haloette, a Generic Version of Nuvaring

Inaugural dividend of AU$0.065 per share

Now 48% undervalued after recent price drop

Mayne Pharma Group Limited (ASX:MYX) agreed to acquire Certain Assets of TherapeuticsMD, Inc. (NasdaqGS:TXMD).

High number of new directors

High number of new directors

Mayne Pharma Group Limited Declares Fully Franked Special Dividend, Payable on 27 January 2023

Catalent, Inc. (NYSE:CTLT) acquired Metrics, Inc. from Mayne Pharma Group Limited (ASX:MYX) for approximately $480 million.

Mayne Pharma Group Limited Announces Executive Changes Effective from 1 October 2022

Mayne Pharma Group Limited Announces Management Changes

Full year 2022 earnings released: AU$0.16 loss per share (vs AU$0.13 loss in FY 2021)

Scott Richards Plans to Retire as CEO of Mayne Pharma Group Limited

FDA Grants Approval to Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA of the Abbreviated New Drug Application (Anda) for Haloette

Mayne Pharma Group Limited and Mithra Pharmaceuticals, Sa Announces NEXTSTELLIS Oral Contraceptive Now Available in Australia

Mayne Pharma Group Limited Announces CFO Changes

Forecast breakeven date pushed back to 2024

First half 2022 earnings: EPS in line with expectations, revenues disappoint

Mayne Pharma Expands U.S Dermatology Portfolio

Insufficient new directors

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Therapeutic Goods Administration Approval of NEXTSTELLIS® Oral Contraceptive

High number of new directors

Independent Non Executive Director Bruce Mathieson has left the company

Independent Chairman Roger Corbett has left the company

Independent Chairman Roger Corbett has left the company

U.S. Food and Drug Administration Approves Mayne Pharma LEXETTE for Adolescent Plaque Psoriasis

Forecast to breakeven in 2023

Independent Non-Executive Director recently bought €85k worth of stock

Full year 2021 earnings released: AU$0.13 loss per share (vs AU$0.061 loss in FY 2020)

Mayne Pharma Group Limited and Mithra Pharmaceuticals, SA Announces Nextstellis Receives FDA Marketing Exclusivity and Phase Iii Data Published

Mayne Pharma Announces New Data Showing Treatment with Nextstellis® Investigational Combined Oral Contraceptive (Coc) Containing Drospirenone (Drsp) and Estetrol

Mayne Pharma Group Limited Launches Another Generic Oral Contraceptive

First half 2021 earnings released: AU$0.12 loss per share (vs AU$0.012 loss in 1H 2020)

Revenue beats expectations

Mayne Pharma Group Limited to Report Fiscal Year 2021 Results on Aug 27, 2021

Mayne Pharma Group Limited Launches MICROGESTIN 24 FE Tablets in the United States

New 90-day high: €0.24

Mayne Pharma Group Limited Provides Update on Women's Health Pipeline

Mayne Pharma Group Limited Appoints Peter Paltoglou as Chief Financial Officer

Full year earnings released

Mayne Pharma Group Limited to Report Fiscal Year 2020 Results on Aug 21, 2020

Mayne Pharma Group Limited(ASX:MYX) dropped from S&P/ASX 200 Index

Gewinn- und Umsatzwachstumsprognosen

Analystenprognosen zum zukünftigen Wachstum

Wachstumsprognosen für den Gewinn je Aktie

Künftige Eigenkapitalrendite

Wachstumsunternehmen entdecken